Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Insulin-Like Growth Factor I, Resistance To 1Fibromatosis, Gingival, 2 1Carcinoma, Hepatocellular 1

Interventions

ganitumab 23-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 2dalotuzumab 1conatumumab 1cixutumumab 1Sorafenib 1Receptor Protein-Tyrosine Kinases 1Paclitaxel 1Lapatinib 1Istiratumab 1Cisplatin 1Capecitabine 1BIIB022 1Antibodies, Monoclonal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Insulin-Like Growth Factor I, Resistance To × Istiratumab × Clear all
NCT01733004 2016-08-04

A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors

Merrimack Pharmaceuticals

Phase 1 Completed
42 enrolled
Gastrointestinal

Insulin-Like Growth Factor I, Resistance To, Carcinoma, Hepatocellular, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡